About ALX Oncology
ALX Oncology is a company based in Burlingame (United States) founded in 2015. It operates as a HealthTech. ALX Oncology has raised $123.02 million across 2 funding rounds from investors including Janus Henderson Investors, HBM Healthcare Investments and Lightstone Ventures. The company has 80 employees as of December 31, 2024. ALX Oncology has completed 1 acquisition, including ScalmiBio. ALX Oncology offers products and services including Evorpacept. ALX Oncology operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
- Headquarter Burlingame, United States
- Employees 80 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alx Oncology Holdings Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-134.85 M16.14as on Dec 31, 2024
-
EBITDA
$-141.59 M16.43as on Dec 31, 2024
-
Total Equity Funding
$123.02 M (USD)
in 2 rounds
-
Latest Funding Round
$105 M (USD), Series C
Feb 12, 2020
-
Investors
Janus Henderson Investors
& 8 more
-
Employee Count
80
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ALX Oncology
ALX Oncology is a publicly listed company on the NASDAQ with ticker symbol ALXO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of ALX Oncology
ALX Oncology offers a comprehensive portfolio of products and services, including Evorpacept. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Evorpacept is developed to boost immune system against cancer.
Unlock access to complete
Unlock access to complete
Funding Insights of ALX Oncology
ALX Oncology has successfully raised a total of $123.02M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $105 million completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series C — $105.0M
-
First Round
First Round
(21 May 2015)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2020 | Amount | Series C - ALX Oncology | Valuation | Vivo Capital | |
| May, 2015 | Amount | Series A - ALX Oncology | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ALX Oncology
ALX Oncology has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Janus Henderson Investors, HBM Healthcare Investments and Lightstone Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund and fund of funds focused on the life science sector
|
Founded Year | Domain | Location | |
|
Venture capital and private equity firm
|
Founded Year | Domain | Location | |
|
Private equity fund focused on the biotechnology sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ALX Oncology
ALX Oncology has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ScalmiBio. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Antibodies are developed to minimize cancer drug side effects.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - ALX Oncology
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Alx Oncology Comparisons
Competitors of ALX Oncology
ALX Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Alx Oncology
Frequently Asked Questions about ALX Oncology
When was ALX Oncology founded?
ALX Oncology was founded in 2015.
Where is ALX Oncology located?
ALX Oncology is headquartered in Burlingame, United States. It is registered at Burlingame, California, United States.
Is ALX Oncology a funded company?
ALX Oncology is a funded company, having raised a total of $123.02M across 2 funding rounds to date. The company's 1st funding round was a Series A of $18.02M, raised on May 21, 2015.
How many employees does ALX Oncology have?
As of Dec 31, 2024, the latest employee count at ALX Oncology is 80.
What does ALX Oncology do?
ALX Oncology is engaged in developing innovative cancer therapies by boosting the immune system. The company is centered on its lead candidate, evorpacept, which is positioned as a potential cornerstone in immuno-oncology. Research and clinical trials are conducted to optimize current and future standards of care in the oncology sector. A synergistic approach is adopted to enhance treatment outcomes for patients.
Who are the top competitors of ALX Oncology?
ALX Oncology's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
What products or services does ALX Oncology offer?
ALX Oncology offers Evorpacept.
Is ALX Oncology publicly traded?
Yes, ALX Oncology is publicly traded on NASDAQ under the ticker symbol ALXO.
How many acquisitions has ALX Oncology made?
ALX Oncology has made 1 acquisition, including ScalmiBio.
Who are ALX Oncology's investors?
ALX Oncology has 9 investors. Key investors include Janus Henderson Investors, HBM Healthcare Investments, Lightstone Ventures, Vivo Capital, and Logos Capital.
What is ALX Oncology's ticker symbol?
The ticker symbol of ALX Oncology is ALXO on NASDAQ.